Lupin launches rheumatoid arthritis drug Leflunomide in US

Written by Ruchika Sharma Published On 2020-09-03T11:58:36+05:30 | Updated On 3 Sept 2020 11:58 AM IST

Lupin launches rheumatoid arthritis drug Leflunomide in US

Mumbai, Baltimore: Drugmaker Lupin Limited has announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

The product would be manufactured at Lupin's Pithampur (Unit I) facility in India.

Leflunomide Tablets USP, 10 mg and 20 mg, is the generic equivalent of Arava® Tablets, 10 mg and 20 mg, of Sanofi-Aventis U.S. LLC., and is indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide Tablets USP (RLD: Arava®) had an annual sales of approximately USD 42 million in the U.S. (IQVIA MAT June 2020).

Read also: Lupin, Mylan launch arthritis drug Nepexto in Germany

Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.

lupinlupin newsleflunomide tabletsusfdaarava tabletsrheumatoid arthritis

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751